◼

News

All News

Keep up to date with the world of Septerna

All

2026

2025

2024

2023

2022

09.10.26

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company’s common stock to Rajiv Patni, M.D., the Company’s newly appointed Chief Medical

09.01.26

Septerna to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences in

08.25.26

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr.

08.10.26

Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results

Phase 1 Clinical Trial Ongoing for SEP-479, an Oral Small Molecule PTH1R Agonist SEP-479 Observed Clinical Pharmacokinetic Profile Supports Once-Daily Dosing; SAD / MAD Data Expected in Q1 2027 Cash Position of $516.5 Million Expected to Support Operating Plans at Least into 2029 SOUTH SAN

06.08.26

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 8, 2026-- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been

05.11.26

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Phase 1 Clinical Trial Initiated for SEP-479, Oral Small Molecule PTH1R Agonist for Hypoparathyroidism Cash Position of

05.05.26

Septerna to Present at Bank of America Securities Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of

04.13.26

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers Data Anticipated in Late 2026 or Early 2027 SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology

03.09.26

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R Agonist) Toward Phase 1 Initiation in First Half of 2026 Cash Runway Expected to Support Operating

03.01.26

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an Adverse Event Profile Comparable to Placebo; Pharmacokinetic Profile Supports

Current page 1
Page 2
Page 3
…
Next page
Last page

Displaying 1 - 10 of 48

News

All News

Pioneering a New Era of GPCR Drug Discovery